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Abstract
Background
Deficiency in dihydropyrimidine dehydrogenase (DPD) enzyme is the main cause of severe
and lethal fluoropyrimidine-related toxicity. Various approaches have been developed for
DPD-deficiency screening, including DPYD genotyping and phenotyping. The goal of this
prospective observational study was to perform exhaustive exome DPYD sequencing and
to examine relationships between DPYD variants and toxicity in advanced breast cancer
patients receiving capecitabine.
Methods
Two-hundred forty-three patients were analysed (88.5% capecitabine monotherapy). Grade
3 and grade 4 capecitabine-related digestive and/or neurologic and/or hemato-toxicities
were observed in 10.3% and 2.1% of patients, respectively. DPYD exome, along with flank-
ing intronic regions 3’UTR and 5’UTR, were sequenced on MiSeq Illumina. DPD phenotype
was assessed by pre-treatment plasma uracil (U) and dihydrouracil (UH2) measurement.
Results
Among the 48 SNPs identified, 19 were located in coding regions, including 3 novel varia-
tions, each observed in a single patient (among which, F100L and A26T, both pathogenic in
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silico). Combined analysis of deleterious variants *2A, I560S (*13) and D949V showed sig-
nificant association with grade 3–4 toxicity (sensitivity 16.7%, positive predictive value
(PPV) 71.4%, relative risk (RR) 6.7, p<0.001) but not with grade 4 toxicity. Considering addi-
tional deleterious coding variants D342G, S492L, R592W and F100L increased the sensitiv-
ity to 26.7% for grade 3–4 toxicity (PPV 72.7%, RR 7.6, p<0.001), and was significantly
associated with grade 4 toxicity (sensitivity 60%, PPV 27.3%, RR 31.4, p = 0.001), suggest-
ing the clinical relevance of extended targeted DPYD genotyping. As compared to extended
genotype, combining genotyping (7 variants) and phenotyping (U>16 ng/ml) did not sub-
stantially increase the sensitivity, while impairing PPV and RR.
Conclusions
Exploring an extended set of deleterious DPYD variants improves the performance of
DPYD genotyping for predicting both grade 3–4 and grade 4 toxicities (digestive and/or neu-
rologic and/or hematotoxicities) related to capecitabine, as compared to conventional geno-
typing restricted to consensual variants *2A, *13 and D949V.
Introduction
Since its launch in 1998, the 5FU oral prodrug capecitabine has gradually become a major
drug and is currently considered as a standard of care for advanced breast cancer. Capecitabine
is ultimately metabolized by thymidine phosphorylase which produces 5FU at target cell level.
Next, intracellularly-produced 5FU enters either the anabolic or the catabolic route. Most
5FU is deactivated into fluorodihydrouracil by ubiquitous dihydropyrimidine dehydrogenase
(DPD), the rate-limiting enzyme of 5FU catabolism, expressed in various human tissues as
well as in human cancer cells [1,2]. Consequently, any DPD activity variation within tumor or
normal cells may have a major repercussion on availability of 5FU for anabolism, and thus
may significantly impact capecitabine pharmacodynamics. DPD deficiency may be considered
as the major cause of capecitabine toxicity, and more generally fluoropyrimidine-related toxic-
ity risk [3–6]. Accordingly, the wide inter-patient variability of DPD enzyme activity measured
in peripheral blood mononuclear cells (PBMC) is significantly correlated to systemic 5FU
clearance in patients receiving i.v. 5FU [3,7]. Of note, breast cancer treatment with capecita-
bine is particularly concerned since PBMC-DPD activity has been shown to be lower in
women as compared to men [7], in line with the observation that women are particularly
prone to suffer from fluoropyrimidine toxicity [8]. Importantly, cases of lethal toxicity have
been reported in patients with marked DPD deficiency after standard 5FU [9] or capecitabine
administration [10–12].
DPD is encoded by DPYD, a large gene spanning 950 kb on chromosome 1p22 (23 exons
comprising 4399 nucleotides) [13]. DPD activity is controlled at both transcriptional and post-
transcriptional levels. Post-transcriptional regulation of DPD involved microRNAs miR-27a
and miR-27b [14]. At transcriptional level, more than 200 polymorphisms have been identified
in DPYD coding regions. In vitro studies have demonstrated that only a few DPYD polymor-
phisms have a significant deleterious impact on enzymatic activity, while even fewer are associ-
ated with proficient (i.e. elevated) enzyme activity [15,16]. It has been clearly demonstrated
that DPYD deleterious variants 2A (c.1905+1G>A), D949V (c.2846A>T), and 13 (I560S,
c.1679T>G) are relevant predictors of fluoropyrimidine-related toxicities [6,17–19]. From a
prospective trial conducted on 2594 colon cancer patients receiving adjuvant 5FU-based
DPYD and capecitabine-related toxicity
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chemotherapy [20], the combined sensitivity of the variants 2A, 13 and D949V to predict
grade 3–4 5FU-related toxicity is only 5.3% (33% toxicity, 2.2% of patients carrying a variant).
The scarcity of these three DPYD variations explains this very low sensitivity: considering at
best 4% of patients carrying one of these three pathological variants and a prevalence of severe
toxicity at 10%, a genetic test based on these 3 variants cannot have a sensitivity greater than
40%. One could thus expect to improve sensitivity by identifying additional relevant variants,
by combining genotyping and phenotyping approaches, or by focusing on the less frequent,
most relevant grade 4 toxicities.
Despite decades of literature data on DPYD pharmacogenetics, very few clinical prospective
studies have reported full DPYD exome sequencing in patients treated by fluoropyrimidines
[21–24], and most of these studies were based on small population subsets. The French GPCO-
Unicancer group recently conducted a prospective observational study on 303 advanced breast
cancer patients receiving capecitabine to assess the impact of pre-treatment DPD and CDA phe-
notype along with a limited number of targeted variants in DPYD (2A, 13, D949V),TYMS and
MTHFR genes, on capecitabine toxicity and efficacy [25]. DPD phenotyping was based on pre-
treatment measurement of plasma uracil (U) and dihydrouracil (UH2). We presently report a
genomic-based complementary study conducted in 243 patients for whom full sequencing of
DPYD exome, along with flanking intronic regions, was performed in order to examine rela-
tionships between DPYD variants and both DPD phenotype and severe capecitabine-related
toxicity.
Patients and methods
Patients
This prospective observational study (Eudract 2008-004136-20) was conducted on 303
advanced breast cancer patients included between February 2009 and February 2011 in 15
French institutions. This study was approved by the "Comite´ de Protection des Personnes—
Me´diterrane´e Sud V" (approval number CPP 08.067). Written informed consent was obtained
for each patient. Among the 303 initially-included patients, 17 were not allocated to the study;
DNA was not available for 16 patients and DPYD sequencing was unsuccessful (poor quality
score) for 27 patients (Fig 1, CONSORT Diagram). Thus, a total of 243 patients were included
in the present analysis (12 recruiting centers). Inclusion criteria were women above 18-years-
old with histologically-proven advanced breast cancer starting capecitabine treatment alone or
in combination with anti-angiogenic therapy, whatever previous metastatic treatment lines
were delivered, provided they did not include a fluoropyrimidine. Previous adjuvant treatment
with fluoropyrimidine was allowed. Exclusion criteria included concomitant chemotherapy or
lapatinib therapy, uncontrolled brain metastasis, uncontrolled chronic illness or infection, life
expectancy lower than 3 months, cardiac failure or hypoxic respiratory failure. Capecitabine
treatment was administered orally in two daily doses for 14 days, followed by 7 days off (day
1 = day 21). The capecitabine dose was left to the discretion of the physician. One to 15 days
before starting treatment, 15 ml of blood were taken in the morning (8 am—11 am) for U and
UH2 plasma analysis and DPYD genotyping. Toxicity (CTCAE v3 criteria) was assessed over
cycles 1–2 (up to 21 days after the end of the 2nd cycle) in 242 patients.
Biological analyses
DPYD sequencing. DNA from total blood (10 ml) was extracted in one out of the 7 partic-
ipating laboratories according to local routine procedures. DNA (1 μg required for DPYD
sequencing) was sent to Integragen (Evry, France) where sequencing was performed. The 23
exons of DPYD gene, along with flanking intronic regions (20 bp), 3’UTR and part of 5’UTR
DPYD and capecitabine-related toxicity
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(580 bp upstream transcription initiation) were sequenced on MiSeq Illumina (PCR multiplex,
2x150 nt paired-end sequencing). Amplicons were sequenced in both directions. Obtained
sequences were mapped to the human reference assembly genome HG19 and variant calling
was performed on the NM_000110 reference transcript. SNPs alignment and variant calling
were performed with the Illumina pipeline CASAVA1.8 using ELANDv2 algorithm. On aver-
age, 97% of target sequences were successfully covered with a mean depth at 1200X. Validated
DNA samples passed quality scores (Q30 quality filter>90%, depth>15X). Indels were identi-
fied using the SNAP/GATK pipeline [26]. Local realignment, base recalibration and haplotype
caller were performed using the GATK tool. INDELs with a quality score>50 and a depth
>10X were selected. Pairwise linkage disequilibria (LD) between bi-allelic DPYD variants were
measured by D’ and D’/LOD calculated on Haploview software v4.2.
In silico functional prediction. In silico pathogenicity prediction of coding variants was
performed with the UMD-Predictor system [27]. Impact of exonic and intronic variations on
splicing signal types was predicted with the Human Splicing Finder system [28].
DPD phenotyping
Blood (5 ml) was immediately placed in an ice-bath, centrifuged at +4˚C for 15 min and frozen
plasma was stored at -80˚C. In order to mimic routine DPD-deficiency screening and ensure
robustness, frozen plasmas were sent to one of 3 measuring laboratories (according to geo-
graphic location). Depending on the laboratory, solid-phase or liquid-liquid extraction fol-
lowed by HPLC analysis (UV detection) of uracil (U) and dihydrouracil (UH2) was performed
[29–31]. Limit of quantification was 7 to 25 ng/ml for UH2 and 3 to 6 ng/ml for U, depending
on the laboratory. A common external quality control (N = 52 aliquots) was shared across the
Fig 1. CONSORT diagram.
https://doi.org/10.1371/journal.pone.0175998.g001
DPYD and capecitabine-related toxicity
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3 laboratories. For UH2, 100% of control values were within +/- 15% of the mean value (92.2
ng/ml) and for U 98% of control values were within +/- 15% of the mean value (7.9 ng/ml)
with one control value at +22%. Regarding the UH2/U ratio, 94% of control values were within
+/- 15% of the mean value (11.7 ng/ml), with 3 values at -25%, -19% and +19%, respectively.
Possible influence of measuring laboratories and recruiting centers on U and UH2/U concen-
trations was checked. Plasma U and UH2/U from patients were not significantly different
between measuring laboratories. In contrast, comparison between recruiting centers showed
that, in one institution U and UH2/U from patients differed significantly from other institu-
tions (ANOVA tests: p<0.001 for both U and UH2/U), suggesting a pre-analytical deviation.
In order to accurately examine the impact of DPYD variants on U and UH2/U plasma concen-
trations, we excluded phenotype data from this recruiting center. In total, two hundred and
five patients with validated DPYD sequencing were thus considered for phenotype analysis.
Statistics
The initial required number of 300 patients was based on the hypothesis that 35% of “at-risk
patients” will develop grade 3–4 capecitabine-related toxicity versus 12% in the group of
patients without risk (unilateral test, alpha = 0.05, beta = 0.10, relative risk = 2.9), with “at-risk
patients” defined as those exhibiting a DPD-deficient phenotype. Hypothesis for DPD-defi-
cient phenotype was UH2/U below 15th percentile or U above the 85th percentile. Considering
patients with validated phenotyping data, actual study power was able to detect a relative risk
(RR) of 3.50. The influence of each individual variant on DPD phenotype and capecitabine-
related toxicity was assessed for DPYD variants present in at least 3 patients, using the non-
parametric Mann-Whitney test and the Fisher Exact test, respectively. DPYD genotypes were
considered as binary variables (wt/wt vs wt/var+var/var). Capecitabine-related toxicity in-
cluded hematotoxicity, digestive toxicity and neurotoxicity. Sensitivity, specificity, positive
predictive value (PPV), negative predictive value (NPV) and relative risk (RR) associated with
DPD-deficiency screening approaches were computed. Sensitivity is defined as the proportion
of patients found to be positive for DPD-deficiency among those experiencing toxicity. Speci-
ficity is defined as the proportion of patients without DPD-deficiency among those without
toxicity. PPV is defined as the proportion of patients experiencing toxicity among those posi-
tive for the test. NPV is defined as the proportion of patients without toxicity among those
negative for the test. RR is defined as the ratio of the toxicity risk in patients positive for the
test to that in patients negative for the test. For the approach combining genotype and pheno-
type, we considered positivity of either one of the two approaches. All tests were two-sided and
were not corrected for multiple testing. All p values 0.05 were reported. Statistics were per-
formed on SPSS software (v15).
Results
Patient characteristics and toxicity
Table 1 describes patients’ characteristics. Mean age was 61.2 years (range 30–88). 88.5% of
patients received capecitabine as monotherapy. Mean capecitabine dose at cycle 1 was 1942
mg/m2/day (median 1964, range 65–2590). Capecitabine-related digestive toxicity, hemato-
toxicity and neurotoxicity, grade (G) 3–4 was observed in 12.4% of patients (30 patients), and
G4 was observed in 5 patients (2.1%), including one toxic death (S1 Table). Hand-foot syn-
drome G3 was observed in 9.5% of patients (no G4). Toxicity was not related to PS status,
patient age, renal function (creatinine clearance), capecitabine treatment line, previous adju-
vant fluoropyrimidine treatment, or capecitabine dose at first cycle. Table 2 details the profile
of patients presenting G4-5 toxicity. A patient with toxic death (80-year-old) presented
DPYD and capecitabine-related toxicity
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presented G4 thrombopenia, G4 diarrhea, G4 renal failure, G5 dyspnea and hypovolemic
shock, 20 days after starting capecitabine monotherapy. This patient had lung and cutaneous
metastases (PS 0, history of arterial hypertension), exhibited uracilemia at 16.7 ng/ml, UH2/U
ratio at 6.5, was heterozygous for D949V polymorphism and carried 2 other variations in
DPYD 3’UTR.
Description of DPYD variants (Table 3)
A total of 65 DPYD variants were identified: 2 SNPs and one INDEL deviated from the Hardy-
Weinberg equilibrium (p<0.07) and 8 SNPs showed poor quality scores or insufficient depth
reading. In total, 54 variants (48 SNPs, 6 INDEL) were validated (mean call rate 98.9%). Fifteen
variants were located at intron 5 (with one SNP and one insertion at same locus 98185720).
Minor allele frequencies (MAF) ranged from 0.2% to 39.7% and were close to those already
Table 1. Patient and treatment characteristics (N = 243).
N %
Performance status
0
1
2
3
Unknown
78
65
21
4
75
32.1
26.7
8.6
1.6
30.9
Previous adjuvant fluoropyrimidine
No
Yes (5FU/capecitabine)
153
90 (89/1)
63%
37%
Metastasis site*
Bone
Liver
Lung
Lymph node
Cutaneous
Brain
Others
161
127
95
62
32
9
12
66.3
52.3
39.1
25.5
13.2
3.7
4.9
Capecitabine treatment
Monotherapy
Concurrent bevacizumab
Concurrent trastuzumab
Concurrent lapatinib**
215
18
7
3
88.5
7.4
2.9
1.2
Capecitabine line
1st line
2nd line
3rd line
 4th line
70
87
61
25
28.8
35.8
25.1
10.3
Number of Capecitabine cycles
 1 cycle
 2 cycles
 3 cycles
243
224
208
100
92.2
85.6
* sum greater than 243 patients due to multiple metastases sites.
** these 3 patients (protocol violation) were kept in final analysis (none developed hematotoxicity, one
developed digestive toxicity (grade 2) and 2 developed cutaneous toxicity (grade 3)).
https://doi.org/10.1371/journal.pone.0175998.t001
DPYD and capecitabine-related toxicity
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reported in Exome Variant Server (build Exome Sequencing Project 6500SI-V2-SSA137) or
HapMap3 (CEU population) databases. The number of variant alleles per patient varied from
0 (8 patients) to 16 (median 3, mean 4, Q1-Q3: 2–5).
In total, 17 novel variations not identified in the dbSNP 141 database were observed (11
SNPs and the 6 INDELs, with MAF comprised between 0.2% and 2.1%). The six observed
INDEL variations were all located in flanking intronic regions (intron 1, 5 and 13). The loca-
tion of the 48 SNPs was as follows: 3 SNPs in 5’UTR; 19 SNPs in coding regions (4 synony-
mous including E412E and 15 missenses, including previously reported D949V, V732I,
R592W, I560S, I543V, S534N, S492L, M406I, D342G, M166V, T65M, C29R and 3 novel varia-
tions A26T, F100L, R696H, each observed in one heterozygous patient); 19 SNPs in flanking
intronic regions (including 2A, with no additional splicing variant) and 7 SNPs in 3’UTR.
Consensual SNP 2A, D949V and I560S were carried by 7 patients (2.9%, all heterozygous).
Table 2. Profile of patients with grade 4–5 toxicity.
Patient #1 Patient #2 Patient #3 Patient #4 Patient #5
Toxicity* Toxic death** (cycle
1)
G4 anemia
G4
thrombopenia
G3 neutropenia
(cycle 1)
G4
thrombopenia
G3 asthenia
(cycle 1)
G3 neurotoxicity
(cycle 1)
G4
thrombopenia
G4 neutropenia
G4 leucopenia
(cycle 2)
G4 diarrhea (cycle
2)
Mean capecitabine dose intensity at cycle 1 (mg/
m2/day)
1530 2030 1790 2490 2170
PS at inclusion 0 1 na 2 0
Pre-treatment UH2/U
Pre-treatment U (ng/ml)
6.5
16.7
14.0
12.9
13.5
22.0
na
na
na
na
DPYD variants
c.-477T>G wt/wt wt/wt VAR/wt wt/wt wt/wt
C29R wt/wt wt/wt VAR/wt wt/wt wt/wt
F100L wt/wt wt/wt wt/wt VAR/wt wt/wt
c.483+837A>G § wt/wt wt/wt VAR/wt wt/wt wt/wt
c.483+1342T>A § wt/wt wt/wt VAR/wt wt/wt wt/wt
c.483+1344T>A § wt/wt wt/wt VAR/wt wt/wt wt/wt
M166V § wt/wt wt/wt VAR/wt wt/wt wt/wt
c.1129-15T>C § wt/wt wt/wt VAR/wt wt/wt wt/wt
S492L wt/wt wt/wt wt/wt wt/wt VAR/wt
D949V VAR/wt wt/wt wt/wt wt/wt wt/wt
c.*274T>C §§ wt/wt VAR/VAR wt/wt wt/wt wt/wt
c.*432T>A wt/wt wt/wt VAR/wt wt/wt wt/wt
c.*768G>A §§ VAR/VAR wt/wt VAR/VAR VAR/VAR wt/wt
c.*780C>T §§ VAR/wt wt/wt VAR/VAR VAR/wt wt/wt
* All grade 3–4 toxicities.
** See Results section for details.
§ these 5 variants were in linkage disequilibria (see S2 Fig).
§§ these 3 variants were in linkage disequilibria (see S2 Fig).
na means not available.
These 5 patients all received capecitabine as monotherapy.
https://doi.org/10.1371/journal.pone.0175998.t002
DPYD and capecitabine-related toxicity
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Table 3. Description of DPYD variations along with in silico / in vitro functionality.
SNP or
INDEL
position (or
rs if any)
Nucleotide
change
and
nomenclature
alias (if any)
Location AA
change
In silico
pathogenicity
prediction
(impact on
splicing signal)
In vitro
functionality
[15] / [16]
wt/
wt
Case
number
var/wt
var/
var
MAF
(%)
Significant
association
with deficient
phenotype*
Significant
association
with
increased
toxicity**
rs145438244 c.-672T>C 5-UTR 241 1 0 0.2 nt nt
rs61787828 c.-477T>G 5-UTR 214 27 1 6.0 NS NS
98386496 c.-18G>A 5-UTR 241 1 0 0.2 na, nt nt
98348989 c.40-69_40-
59del
Intron 1 (No impact on
splicing)
242 1 0 0.2 nt nt
98348894 c.76G>A Exon 2 A26T Pathogenic
(ESE site
broken)
- / - 241 1 0 0.2 nt nt
rs1801265 c.85T>C (*9A) Exon 2 C29R Benign
(ESE site broken,
new ESS)
- / Slightly
deficient
161 74 7 18.2 NS No***
rs371587702 c.194C>T Exon 3 T65M Pathogenic
(ESE site
broken)
Benign / - 241 1 0
0.2 nt
nt
98205969 c.300C>A Exon 4 F100L Pathogenic
(ESE site
broken)
F100[FS] very
deficient / -
241 1 0
0.2 na, nt
nt
rs56276561 c.483+18G>A # Intron 5 (No impact on
splicing)
238 4 0 0.8 NS NS
98186503 c.483+563T>C Intron 5 (No impact on
splicing)
241 1 0
0.2 nt
nt
98186337 c.483+729G>A Intron 5 (No impact on
splicing)
241 1 0
0.2 nt
nt
rs56066952 c.483+834A>G Intron 5 (No impact on
splicing)
240 2 0 0.4 nt nt
rs55684412 c.483+837A>G Intron 5 (No impact on
splicing)
195 44 3 10.3 NS NS
98185786 c.483
+1280A>G
Intron 5 (No impact on
splicing)
242 1 0 0.2 nt nt
rs61786599 c.483
+1342T>A
Intron 5 (No impact on
splicing)
202 40 1 8.6 NS NS
rs61786598 c.483
+1344T>A
Intron 5 (No impact on
splicing)
192 48 3 11.1 NS NS
98185721 c.483
+1345_483
+1354del
Intron 5 (No impact on
splicing)
242 1 0 0.2 nt nt
rs199919864 c.483
+1346A>T
Intron 5 (No impact on
splicing)
242 1 0 0.2 na, nt nt
98185720 c.483
+1345_483
+1346dup
Intron 5 (No impact on
splicing)
241 2 0 0.4 nt nt
98185711 c.483
+1354_483
+1355insAA
Intron 5 (No impact on
splicing)
242 1 0 0.2 nt nt
98185705 c.483
+1360_483
+1361dup
Intron 5 (No impact on
splicing)
233 10 0 2.1 NS NS
rs75848562 c.483
+1366A>G
Intron 5 (No impact on
splicing)
232 11 0 2.3 NS NS
rs142148197 c.483
+1689G>A
Intron 5 (No impact on
splicing)
242 1 0 0.2 nt nt
(Continued )
DPYD and capecitabine-related toxicity
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Table 3. (Continued)
SNP or
INDEL
position (or
rs if any)
Nucleotide
change
and
nomenclature
alias (if any)
Location AA
change
In silico
pathogenicity
prediction
(impact on
splicing signal)
In vitro
functionality
[15] / [16]
wt/
wt
Case
number
var/wt
var/
var
MAF
(%)
Significant
association
with deficient
phenotype*
Significant
association
with
increased
toxicity**
rs2297595 c.496A>G Exon 6 M166V Benign
(New ESS site
and cryptic
acceptor splice
site)
Proficient /
Slightly
deficient
198 42 3 9.9 NS NS
98060744 c.851-22T>C Intron 8 (No impact on
splicing)
241 1 0 0.2 nt nt
rs183385770 c.1025A>G Exon 10 D342G Pathogenic
(ESE site broken,
new ESS site)
D342N very
deficient / -
241 1 0 0.2
nt
nt
98058849 c.1053T>C Exon 10 A351A Benign
(No impact on
splicing)
241 1 0 0.2 nt nt
98058804 c.1098C>T Exon 10 G366G Probably
pathogenic
(New ESS site)
241 1 0 0.2 na, nt nt
rs56293913 c.1129-15T>C Intron 10 (No impact on
splicing)
191 46 5 11.6 NS NS
rs61622928 c.1218G>A Exon 11 M406I Benign
(No impact on
splicing)
Benign /
Benign
242 1 0 0.2 nt nt
rs56038477 c.1236G>A # Exon 11 E412E Benign
(No impact on
splicing)
239 4 0 0.8 NS NS
rs72549304 c.1475C>T Exon 12 S492L Pathogenic
(New ESS site)
Very deficient /
-
241 1 0 0.2 na, nt nt
rs199469537 c.1524 +16C>A Intron 12 (No impact on
splicing)
- 241 1 0 0.2 na, nt nt
rs1801158 c.1601G>A (*4) Exon 13 S534N Probably benign
(New ESS site)
- / Slightly
deficient
234 8 0 1.7 NS NS
rs1801159 c.1627A>G Exon 13 I543V Benign
(No impact on
splicing)
- / Benign 161 73 8 18.4 NS NS
rs55886062 c.1679T>G
(*13)
Exon 13 I560S Pathogenic
(No impact on
splicing)
Very deficient /
-
242 1 0 0.2 na, nt nt
97981200 c.1740+82del Intron 13 (No impact on
splicing)
242 1 0 0.2 nt nt
rs59086055 c.1774C>T Exon 14 R592W Pathogenic
(New ESS site)
Very deficient /
-
241 1 0 0.2 nt nt
rs17376848 c.1896T>C Exon 14 F632F Benign
(New ESS site)
227 15 1 3.5 NS NS
rs3918290 c.1905+1G>A
(*2A)
Splice
intron 14
Pathogenic
(Alteration of the
donor site)
Very deficient / 240 3 0 0.6 Yes Yes
rs369990607 c.1905+17A>G Intron 14 (No impact on
splicing)
242 1 0 0.2 nt nt
rs12078940 c.1906-24G>A Intron 14 (No impact on
splicing)
241 1 0 0.2 nt nt
(Continued)
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Table 3. (Continued)
SNP or
INDEL
position (or
rs if any)
Nucleotide
change
and
nomenclature
alias (if any)
Location AA
change
In silico
pathogenicity
prediction
(impact on
splicing signal)
In vitro
functionality
[15] / [16]
wt/
wt
Case
number
var/wt
var/
var
MAF
(%)
Significant
association
with deficient
phenotype*
Significant
association
with
increased
toxicity**
97771825 c.2087G>A Exon 17 R696H Probably
pathogenic
(No impact on
splicing)
- / - 241 1 0 0.2 nt nt
rs55846082 c.2179+28C>T Intron 17 (No impact on
splicing)
241 1 0 0.2 nt nt
rs138637410 c.2179+29G>A Intron17 (No impact on
splicing)
241 1 0 0.2 na, nt nt
rs1801160 c.2197G>A (*6) Exon 18 V732I Benign
(No impact on
splicing)
V732G benign
/
V732I Slightly
deficient
226 16 0 3.3 NS NS
rs67376798 c.2846A>T Exon 22 D949V Probably
pathogenic
(ESE site broken,
new ESS site)
Moderately
deficient /
Moderately
deficient
240 3 0 0.6 Yes Yes
rs56160474 c.*274T>C 3-UTR 158 75 9 19.2 NS NS
rs188501488 c.*432T>A 3-UTR 240 2 0 0.4 nt nt
rs291592 c.*768G>A 3-UTR 85 122 35 39.7 NS NS
rs291593 c.*780C>T 3-UTR 151 78 13 21.5 NS NS
rs17470762 c.*900T>C 3-UTR 222 19 1 4.3 NS NS
rs41285690 c.*1062A>G 3-UTR 238 4 0 0.8 NS NS
97543343 c.*1189G>A 3-UTR 241 1 0 0.2 nt nt
SNP and INDEL positions are given relative to genome build 37 HG19 (reference = nucleotide A of the translation initiation codon ATG).
In silico pathogenicity of coding variants was predicted using UMD-Predictor system [27]. The potential impact of exonic and intronic variations on splicing
signal types was predicted using Human Splicing Finder system [28].
In vitro functionality derived from two published in vitro functional studies [15,16] reporting DPD enzyme activity of missense DPYD variants transgenically
expressed in mammalian cells. In both studies, deficiency and proficiency were based on statistical comparison relative to wild-type DPD activity (100%
activity). p value considered statistically significant was 0.05 in the study by Offer [15] and 0.001 in the study by van Kuilenburg [16]. Statistically significant
DPD deficiency was classified as “Very deficient” for DPD activity25% wild-type DPYD, “Moderately deficient” for DPD activity within 25–60% that of wild-
type, and “Slighly deficient” for DPD activity >60% that of wild-type. Otherwise, variant functionality was considered benign (not statistically significant) or
proficient when significantly greater than that of wild-type.–means that the variant was not tested in vitro.
MAF means minor allelic frequency, expressed as a percentage.
* Impact of each DPYD variation on phenotype (UH2/U or U) was tested by means of non-parametric Mann-Whitney test for variants present in at least 3
patients (see Statistics section and Fig 2 for details).
** Impact of each DPYD variation on digestive/hemato/neurotoxicity (grade 3-4-5 or grade 4–5) was tested by means of Fisher Exact test for variants
present in at least 3 patients (see Statistics section).
*** Patients bearing variant allele C29R significantly experienced less toxicity than wt patients (p = 0.041).
# Variant linked to haplotype B3 comprising synonymous variant E412E and three intronic variants c.483+18G>A, c.680+139G>A and c.959-51T>C.
ESE means exonic splicing enhancer; ESS means exonic splicing silencer.
nt means not tested due to scarcity of variant carriers (less than 3 patients bearing at least one variant allele).
na means that DPD phenotype was not available (lack of validated UH2/U or U plasma concentration).
NS means not significant (p0.05).
Yes means that a significant relationship (p<0.05) was observed (see details in the Results section).
https://doi.org/10.1371/journal.pone.0175998.t003
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The location of the 19 observed exonic variants relative to DPD protein structure is shown in
S1 Fig. Of note, F100L was located within the N-terminal Fe-S cluster containing the alpha
helical domain I (Fig 2). No large intragenic deletion in the DPYD gene was observed by multi-
plex ligation-dependent probe amplification in the 30 patients with G3-4 toxicity (unshown
data).
Analysis of pairwise linkage disequilibrium (LD) between the 52 bi-allelic variants (located
at different loci) showed that mainly 2 regions were prone to LD: one restricted to 3’UTR and
a second large region ranging from intron 5 till exon 11 (S2 Fig). This second region included
c.483+18G>A and E412E that composed haplotype B3 (HapB3), along with 5 other linked
SNPs (c.483+837A>G, c.483+1342T>A, c.483+1344T>A, M166V, c.1129-15T>C). HapB3
inference was highly likely for the 4 patients bearing E412E variant since they also exhibited
the c.483+18G>A variation (all heterozygous).
For the 19 exonic SNPs, results of in silico pathogenicity (deficiency) prediction showed 7
variants predicted as pathogenic (including novel variants A26T and F100L), 3 as probably
pathogenic (including novel variant R696H), and 9 as benign or probably benign (Table 3).
Table 3 also depicts in vitro functionality reported in the literature [15,16] for known missense
DPYD variations. D342G was not tested in vitro but codon 342 variation D342N was very defi-
cient in vitro. Codon 100 variation F100[FS] was previously associated with loss of enzyme
activity in vitro. A discrepancy was observed between in silico and in vitro functionality for var-
iant T65M (proficiency not assessable by means of the UMD-Predictor tool).
Association between DPYD variants and DPD phenotype
For the 205 patients with validated phenotypic data, mean pre-treatment plasma UH2/U ratio
was 11.1 (median 10.6, Q1-Q3 8.2–12.9, range 0.1–36) and mean plasma U was 10.9 ng/ml
(median 9.6, Q1-Q3 7.7–12.2, range 3.9–75.3). The sum of variant alleles did not impact UH2/
U or U concentrations. Fig 3 illustrates the distribution of UH2/U and U plasma concentra-
tions according to DPYD variants with very deficient (R592W, 2A, related-D342N) or moder-
ately deficient (D949V) enzyme activity in vitro, as well as M166V and HapB3. Only variant
2A and D949V were associated with a low UH2/U ratio (p = 0.039 and 0.008, respectively).
Only variant D949V was associated with an elevated U concentration (p = 0.005).
Association between DPYD variants and toxicity
Analysis of the impact of each individual DPYD variant on toxicity showed that only variant
D949V and 2A were significantly associated with an increased risk of developing grade 3–4
toxicity, with similar performance level: 66.7% (2/3) toxicity in wt/var patients vs 11.8% (28/
239) in wt/wt patients (sensitivity 6.7%, specificity 99.5%, RR 5.69, 95%CI 2.38–13.6,
Fig 2. Location of F100L variant within the N-terminal Fe-S cluster containing the alpha helical
domain I of the DPD protein. Protein modeling was performed using UCSF Chimera version 1.8. The pig
crystal structure (PDB ID 1gTH) was used as a template. The F100L variant could impair enzyme function by
disrupting a conserved residue F100 important for electron transfer via the [4Fe-4S] cluster.
https://doi.org/10.1371/journal.pone.0175998.g002
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p = 0.041). D949V and 2A variants had no significant impact when focusing on grade 4 toxic-
ity. Of note, the only patient carrying the S492L allele and the patient carrying the F100L allele,
both developed grade 4 toxicity (Table 2).
Predictive value of DPYD variants in combination was next examined (Table 4). The pres-
ence of one deficient allele among consensual variants 2A, D949V or I560S was significantly
associated with grade 3–4 toxicity (sensitivity 16.7%, PPV 71.4%, RR 6.71, 95%CI 3.7–12.2,
p<0.001) but was not predictive of grade 4 toxicity. We then considered the 11 in silico patho-
genic or probably pathogenic variants (2A, 13, D949V, A26T, T65M, F100L, D342G,
G366G, S492L, R592W, R696H). All these variants had very low MAF (<1%) and were only
observed in heterozygous state. This set of 11 in silico deleterious variants was significantly
associated with both grade 3–4 (sensitivity 26.7%, PPV 53.3%, RR 5.48, p<0.001) and grade 4
hemato-digestive-neurotoxicity (sensitivity 60%, PPV 20%, RR 22.6, p = 0.002, Table 4).
Finally, we considered together variants 2A, D949V and I560S associated with all variants
having shown very deficient (<25%) or moderately deficient (25–60%) in vitro enzyme activity
Fig 3. Distribution of pre-treatment plasma UH2/U ratio (A) and Uracil concentrations (B) for the 205 patients
with validated phenotypic data, according to DPYD variants of interest: variant *2A (3 heterozygous patients),
D949V (3 heterozygous patients), R592W (1 heterozygous patient), D342G (1 heterozygous patient), HapB3
(4 heterozygous patients), 166VV (3 homozygous patients) vs any other variations (185 patients) vs no
variation (5 patients). DPD deficiency is reflected by plasma UH2/U decrease or plasma uracil increase. All
indicated genotypes were mutually exclusive. Horizontal solid lines indicate median values (10.6 for UH2/U
and 9.6 ng/ml for Uracil concentration). Horizontal dotted line on Uracil plot indicates the 91st percentile (16
ng/ml) associated with enhanced grade 3–4 toxicity. Open diamonds indicate patients with toxicity grade 0-1-
2 and solid bow ties indicate patients with grade 3–4 toxicity. For variants carried by at least 3 patients,
distribution of phenotype was compared between carriers and non-carriers using the non-parametric Mann-
Whitney test (* indicates 0.01p<0.05 and ** indicates p<0.01).
https://doi.org/10.1371/journal.pone.0175998.g003
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relative to wild-type (i.e. S492L, R592W, and related-variations D342G and F100L). Taking
into account the 7 above-cited in vitro deleterious DPYD alleles (all mutually exclusive)
improved the performance of the genotyping test relative to both the 3 consensual variants
and the 11 in silico deleterious variants, on both grade 3–4 (sensitivity 26.7%, PPV 72.7%, RR
7.6, p< .001) and grade 4 toxicities (sensitivity 60%, PPV 27.3%, RR 31.4, p = 0.001, Table 4).
In patients with validated phenotypic data, distribution of UH2/U was not different accord-
ing to toxicity. In contrast, uracilemia was higher in patients developing grade 4 toxicity rela-
tive to patients who did not (Mann-Whitney test p = 0.016). Patients with uracilemia above 14
ng/ml (i.e. 85th percentile = initial hypothesis) were significantly prone to develop grade 4 tox-
icity (Fisher Exact test p = 0.047), however significance was not reached when regarding grade
Table 4. Association of variant combinations and/or DPD phenotype with capecitabine-related toxicity (maximum toxicity grade considering
hematotoxicity, digestive and neurotoxicity).
Tested biomarkers
Patients
at risk
Grade 3–4 toxicity Grade 4 toxicity
/ N total Sens. Spe. PPV NPV RR
(95%CI)
N event p # Sens. Spe. PPV NPV RR
(95%CI) N
event
p #
Three consensual
variants (*2A, I560S,
D949V)*
2.9%
(7/242)
16.7% 99.1% 71.4% 89.4% 6.71
(3.69–
12.2)
12.4%
(30)
<0.001 20% 97.5% 14.3% 98.3% 8.39
(1.07–
65.7)
2.1%
(5)
0.14
Seven in vitro
deleterious variants** 4.6%
(11/241)
26.7% 98.6% 72.7% 90.4% 7.60
(4.44–
13.0)
12.4%
(30)
<0.001 60% 96.6% 27.3% 99.1% 31.36
(5.8–
168.9)
2.1%
(5)
0.001
Eleven in silico
deleterious
variants***
6.2%
(15/241)
26.7% 96.7% 53.3% 90.3% 5.48
(2.95–
10.16)
12.4%
(30)
<0.001 60% 94.9% 20.0% 99.1% 22.6
(4.08–
125.1)
2.1%
(5)
0.002
U >16 ng/ml
9%
(18/203)
##
12.5% 91.6% 16.7% 88.6% 1.47
(0.48–
4.45)
11.8%
(24)
0.45 66.7% 92% 11.1% 99.5% 20.56
(1.96–
215.8)
1.5%
(3)
0.021
Combined U>16 ng/
ml and/or consensual
variants*
10.3%
(21/203)
20.8% 91.1% 23.8% 89.6% 2.28
(0.95–
5.47)
11.8%
(24)
0.082 66.7% 90.5% 9.5% 99.5% 17.33
(1.64–
183.1)
1.5%
(3)
0.029
Combined U>16 ng/
ml and/or in vitro
deleterious variants**
10.9%
(22/202)
25.0% 91.0% 27.3% 90.0% 2.73
(1.21–
6.14)
11.9%
(24)
0.030 66.7% 89.9% 9.1% 99.4% 16.36
(1.55–
173.2)
1.5%
(3)
0.032
* The number of patients developing grade 3–4 toxicity among patients carrying DPYD variants was 2/3 for variant *2A, 1/1 for variant *13, 2/3 for variant
D949V, 1/1 for variant F100L, 0/1 for variant D342G, 1/1 for variant S492L, 1/1 for variant R592W. All these variants were mutually exclusive.
** In vitro deleterious variants were *2A, I560S, D949V, F100L, D342G, S492L R592W (See Table 3 for details and literature references).
*** In silico deleterious variants were *2A, I560S, D949V, A26T, T65M, F100L, D342G, G366G, S492L, R592W, R696H (see Table 3 for details).
#p value of the Fisher Exact test.
##on this subset of 203 patients, association between either the presence of one variant among the 3 or 7 deleterious DPYD variants and grade 3–4 toxicity
was confirmed (p = 0.002 and 0.001, respectively) but association with grade 4 toxicity was not.
Sens means sensibility (% of patients positive for the tested biomarker among those experiencing toxicity), Spe means specificity (% of patients negative for
the tested biomarker among those without toxicity), PPV means positive predictive value (% of patients experiencing toxicity among those positive for the
tested biomarker), NPV means negative predictive value (% of patients without toxicity among those negative for the tested biomarker), RR means relative
risk (ratio of the toxicity risk in patients positive for the tested biomarker to that in patients negative for the tested biomarker), NS means not significant.
https://doi.org/10.1371/journal.pone.0175998.t004
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3–4 toxicity. Best uracilemia cutoff was 91st percentile: elevated uracilemia above 16 ng/ml was
significantly associated with a RR of 20.6 to develop grade 4 toxicity (sensitivity 66.7%, PPV
11.1%, RR 20.6, p = 0.021) (Table 4). As compared with genotyping of either 3 consensual var-
iants, or 7 in vitro deleterious, or 11 in silico deleterious variants, the combined genotype-phe-
notype approach (uracil > 16 ng/ml and/or the presence of deleterious DPYD allele) did not
improve toxicity prediction. For instance, with the best combined approach (7 in vitro deleteri-
ous variants) sensitivity dropped from 26.7% to 25%, PPV from 72.7% to 27.3%% and RR
from 7.6 to 2.7 for grade 3–4 toxicity; for grade 4 toxicity sensitivity increased from 60% to
66.7%, and PPV dropped from 27.3% to 9.1% and RR from 31.4 to 16.4 (Table 4).
Discussion
Capecitabine can induce side-effects that not only impair quality of life and treatment efficacy
but may also lead to life-threatening toxicity. Large studies have reported that capecitabine can
induce 10% to 25% grade 3–4 digestive toxicity and/or hematotoxicity, 3–10% hand-foot syn-
drome and 0.2% to 0.6% lethal toxicity [12,22,23,32]. The present observational prospective
study conducted on 243 breast cancer patients receiving capecitabine (monotherapy in major-
ity) showed one lethal toxicity (0.4%), 12.4% grade 3–4 hemato/digestive/neurotoxicity and
9.5% grade 3 hand-foot syndrome, in line with literature data. For decades, DPD deficiency
has been shown to be the main cause of severe and lethal fluoropyrimidine-related toxicity.
Various analytical approaches have been developed for DPD-deficiency screening [33], includ-
ing direct (PBMC enzyme activity) or indirect (measurement of pyrimidine metabolites) phe-
notyping, or DPYD genotyping. However, a still open question is how to faithfully identify
patients at risk of toxicity. Our goal was to analyze exhaustive exome DPYD variations and
examine their possible relationships with capecitabine-related toxicity and DPD phenotype
assessed by pre-treatment plasma U or UH2/U concentrations, considered as a surrogate
marker of DPD enzyme activity [29]. To our knowledge, this study is so far the largest prospec-
tive one reporting full DPYD exome sequencing in patients receiving fluoropyrimidine.
In total, DPYD sequencing revealed 54 variants, of which 19 exonic variations including 15
missenses (Table 3). In vitro functionality has already been reported for 11 presently-observed
missense variations, with conflicting results for M166V variant only [15,16]. These two in vitro
studies reported significantly severe reduced enzyme activity (25% relative to wild-type) for
variants S492L, I560S, and R592W, moderate reduced activity (25–60% relative to wild-type)
for variant D949V, while other variations showed either slight deficiency (>60% relative to
wild-type) or no non-functional impact [15,16]. In line with in vitro data, variants I560S,
R592W and S492L were predicted as pathogenic, and D949V was predicted as probably patho-
genic, in silico. The presently-observed D342G variation has never been tested in vitro but
D342N has been associated with very deficient enzyme activity [15]. For novel variant F100L,
related in-frame 3-nucleotide insertion F100[FS] (rs72549301) at codon 100 has been associ-
ated with dramatic loss of activity in vitro [15]. Accordingly, D342G and novel F100L varia-
tions were predicted as pathogenic in silico. In total, these seven infrequent DPYD-deficient
alleles (I560S, S492L, R592W, D342G, D949V, F100L and variant 2A) were observed at het-
erozygous status and were mutually exclusive in the present patient cohort.
Other DPYD variants of potential interest are those involved in Haplotype B3 (HapB3),
highlighted as a significant predictor of fluoropyrimidine toxicity in a recent meta-analysis
[19]. HapB3 comprised variant E412E, c.483+18G>A, and 2 other intronic variants not pres-
ently analyzed (c.680+139G>A, c.959-51T>C) [34]. HapB3 is also in tight linkage with the
deleterious deep intronic variant c.1129-5923C>G [35]. Four patients carried the E412E allele
(heterozygous) and were also the only ones to exhibit c.483+18G>A variation (heterozygous),
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strongly suggesting that they carried HapB3. As concerns INDELs, the relevant duplication
c.168_175dupGAATAATT in exon 3 (in silico pathogenic) identified in a DPD-deficient
patient with lethal toxicity [31] was not found in the present patient cohort.
In complement to DPYD genotyping, we indirectly analyzed DPD phenotype by measuring
physiological plasma U and UH2 concentrations, which is a more widely applicable approach
than direct measurement of PBMC-DPD activity. Only 2A and D949V were significantly
associated with DPD-deficient phenotype (I560S, S492L and F100L not tested due to lack of
phenotype data) (Fig 3, Table 3). The single patient bearing R592W variant and the one carry-
ing D342G, both expressed low UH2/U ratios. No clear link between phenotype and genotype
emerged for HapB3 (4 heterozygous patients), nor for variant M166V (3 homozygous patients)
(Fig 3). The patient with the most proficient phenotype (uracilemia 3.9 ng/ml) was heterozy-
gous for variant I543V and for 3’UTR variant rs291592. The most deficient patient (uracilemia
75 ng/ml) was heterozygous for variant C29R, two 3’UTR variants (rs56160474, rs41285690)
and one 5’UTR variant (rs61787828).
The main objective of this prospective study was to examine relationships between DPYD
genotype and capecitabine-related toxicity. Consistent with phenotype data, single variant
analyses revealed that only 2A and D949V were significantly associated with an increased risk
of grade 3–4 digestive, hemato or neuro-toxicities, in line with literature data [22]. The four
HapB3 carriers did not present any trend for increased toxicity (no grade 3–4), in line with the
results of a recent large prospective study conducted on 1228 5FU-treated patients [36]. The
novel in silico pathogenic F100L variant was carried by a single patient who developed a grade
4 hematotoxicity associated with grade 3 neurotoxicity (Table 2). Interestingly, codon F100 is
a very conserved residue located within the N-terminal 4Fe-4S cluster containing the alpha
helical domain I of the enzyme (S1 Fig). This cluster plays an important role in the electron
transfer responsible for the reduction reaction catalyzed by DPD enzyme (Fig 2). This clinical
observation, along with in silico prediction and in vitro data reported for related-variant F100
[FS] [15], strongly suggests that infrequent variant F100L may be the causal origin of severe
fluoropyrimidine-related toxicity.
Sensitivity of genotyping considering the 3 consensual variants 2A, D949V and I560S
together was 16.7% for grade 3–4 toxicity (RR 6.7, p<0.001) and was not significant on grade 4
toxicity (Table 4). In order to perform variant combinations as objectively as possible, two
combination approaches were tested, one based on in silico prediction using the UMD-Predic-
tor system [27], the other relying on existing in vitro functional data reporting DPD enzyme
activity in transgenically-expressed missense DPYD variants [15,16]. The best performance
was observed with the combined seven in vitro deleterious variants (Table 4). As compared to
the 3 consensual variants, adding in vitro deleterious variants D342G, S492L, R592W and
F100L increased the sensitivity to 26.7% for grade 3–4 toxicity, with a similar RR (7.6, p<
0.001). Moreover, the combination of the seven in vitro deleterious variants was significantly
associated with grade 4 toxicity (sensitivity 60%, RR 31.4, p = 0.001) (Table 4). Present results
show that extended DPYD genotyping to known in vitro deficient variants clearly improves the
performance of consensual DPYD genotyping for pre-emptive identification of patients at-risk
to develop severe fluoropyrimidine-related toxicities. An alternative strategy, although proba-
bly more time-consuming, may be to perform exome DPYD sequencing, and consider in silico
prediction of coding variations. Even though the present study shows this latter approach to be
less effective, both strategies deserve to be validated in a future prospective study.
Previous studies have suggested that pre-treatment plasma UH2/U or U is associated with
fluoropyrimidine toxicity [30]. A recent large Dutch study [12] confirmed that pre-treatment
plasma U is associated with global severe toxicity in patients receiving capecitabine. In the
present patient cohort, pretreatment UH2/U ratio and uracil concentrations were not
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significantly different between patients with or without grade 3–4 capecitabine toxicity
(unshown data). However, patients presenting very high plasma U (>16 ng/ml, 91st percentile)
were significantly prone to develop grade 4 toxicity relative to patients with U below 16 ng/ml
(sensitivity 66.7%, RR 20.6, p = 0.021, Table 4). Finally, identifying at-risk patients based on
either deficient phenotype (U>16 ng/ml) and/or deficient genotype did not substantially
increase sensitivity as compared to genotype alone, while impairing toxicity predictive value
and relative risk (Table 4). Present results suggest that the best approach for preventing grade
3–4 toxicity would be extended DPYD genotype, while prevention of more severe grade 4 tox-
icity may be based on plasma uracil only. The weak association between indirect DPD pheno-
typing (uracil, UH2/U) and grade 3–4 capecitabine-related toxicity may reflect the lack of
correlation reported between PBMC-DPD enzyme activity and plasma UH2/U ratio, while a
significant but weak correlation was observed between plasma U and PBMC activity [16]. This
poor correlation between physiological pyrimidine concentrations and DPD enzyme activity
may reflect the fact that, under low physiological U concentrations, DPD enzyme is not satu-
rated, suggesting that only a marked DPD deficiency can impact physiological U and UH2
concentrations. Accordingly, literature data show that, in most cases, lethal toxicity is associ-
ated with a markedly deficient phenotype based on physiological pyrimidines in plasma
[10,12,31], or enzyme activity [5]. In line, the lethal toxicity observed in the present study
occurred in a patient presenting elevated U plasma concentration (above the 91st percentile).
These observations fully justify the need to implement DPD-deficiency screening based on
indirect or direct DPD phenotyping approaches for preventing lethal toxicities. An alternative
possible relevant phenotyping approach is to explore uracil metabolism after administration of
a loading dose of uracil that results in temporary DPD enzyme saturation [37,38]. Toxicity pre-
vention of capecitabine-based chemotherapies may be improved by additional biomarkers
linked to the regulation of DPD expression, such as miR-27a and more specifically MIR27A
rs895819 polymorphism [39], or to polymorphisms in other genes related to capecitabine
pharmacology, such as MTHFR, CDA, TYMS or ENOSF1 [40,41,42] that have been shown to
be associated with capecitabine toxicity.
In conclusion, DPD-deficiency is recognized to be a leading cause of severe fluoropyrimidine
toxicity [6,17] and a recent prospective study has demonstrated that fluoropyrimidine dose-
adjustment based on upfront DPYD 2A genotyping (dose reduced by>50% in heterozygous
carriers) was feasible, cost-effective, and improved safety [43]. Present results extend our under-
standing of deleterious DPYD variants and emphasize their potential impact on the toxicity of
capecitabine-based treatments. A next step would be to establish whether upfront fluoropyrimi-
dine dose-adjustment based on an extended DPD-deficiency screening approach could further
improve safety without impairing treatment efficacy, while remaining cost-effective.
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